HALO Halozyme Therapeutics Earnings and EPS analysis

EPS in 2025 (TTM): $4.89

Last Report Period Date: Sep 30, 2025

As of November 2025, HALO's current EPS stands at $4.89, according to the latest financial reports. For the year 2024, the company recorded an earnings per share (EPS) of $3.5, which marks an increase compared to its EPS of $2.13 in 2023. HALO reported an EPS of $1.49 for the quarterly report ending on Sep 30, 2025.

For 2024, Halozyme Therapeutics's EPS was $3.5, an increase of 64.3% from $2.13 in 2023. For the fiscal quarter that ended on Sep 30, 2025, the per-share earnings was $1.49, showing a 38% increase from the same quarter last year. For the twelve months ending September 2025, the EPS is $4.89. For the year 2023, the yearly earnings per share was $2.13, marking an increase of 43.9% from 2022.

Halozyme Therapeutics has registered an increase in EPS of 38% during the last 12 months (YoY, quarterly). Throughout the last three years, the company had an average EPS growth of 7% per year.